Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Summit Therapeutics Inc’s stock clocked out at $17.94, up 5.41% from its previous closing price of $17.02. In other words, the price has increased by $5.41 from its previous closing price. On the day, 2.97 million shares were traded. SMMT stock price reached its highest trading level at $18.085 during the session, while it also had its lowest trading level at $16.8101.
Ratios:
To gain a deeper understanding of SMMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On September 17, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $13.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $40.Guggenheim initiated its Buy rating on September 04, 2025, with a $40 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 21 ’25 when Xia Yu bought 533,617 shares for $18.74 per share. The transaction valued at 9,999,983 led to the insider holds 32,057,147 shares of the business.
DUGGAN ROBERT W bought 26,680 shares of SMMT for $499,983 on Oct 21 ’25. The Co-Chief Executive Officer now owns 76,680 shares after completing the transaction at $18.74 per share. On Oct 21 ’25, another insider, Zanganeh Mahkam, who serves as the Co-Chief Executive Officer of the company, bought 26,680 shares for $18.74 each. As a result, the insider paid 499,983 and bolstered with 76,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 13355299840 and an Enterprise Value of 13122172928.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.51, which has changed by -0.04756576 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $15.55. The 50-Day Moving Average of the stock is -6.21%, while the 200-Day Moving Average is calculated to be -18.29%.
Shares Statistics:
It appears that SMMT traded 3.62M shares on average per day over the past three months and 2588180 shares per day over the past ten days. A total of 744.44M shares are outstanding, with a floating share count of 102.73M. Insiders hold about 86.17% of the company’s shares, while institutions hold 14.08% stake in the company. Shares short for SMMT as of 1764288000 were 32347593 with a Short Ratio of 8.94, compared to 1761868800 on 32436319. Therefore, it implies a Short% of Shares Outstanding of 32347593 and a Short% of Float of 27.310000000000002.
Earnings Estimates
. The current market rating for Summit Therapeutics Inc (SMMT) reflects the collective analysis of 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.04, with high estimates of $0.71 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.1 and -$1.12 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.74, with 10.0 analysts recommending between -$0.43 and -$1.18.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $1.89M in the next fiscal year. The high estimate is $44.12M and the low estimate is -$62.12M.
